StoxRubicon Research Ltd.
NSE: RUBICON · Healthcare
Ask the data
Instant answers about Rubicon Research Ltd. — computed from its filings, no language modelPrice & valuation
split & bonus adjusted · pick a metric and rangeAnnual performance
annual · ₹ crore · line = operating margin| FY26 | |
|---|---|
| Revenue | 1,754 |
| EBITDA | 400 |
| Operating margin | 22.8% |
| Interest | 42 |
| Depreciation | 45 |
| Profit before tax | 321 |
| Tax | 74 |
| Net profit | 247 |
| EPS ₹ | 15.52 |
| Operating cash flow | 205 |
| Capex | 229 |
| Dividend paid | 0 |
| Total assets | 2,327 |
| Equity | 1,289 |
Quarterly performance
last 5 quarters · ₹ crore| SEP '25 | DEC '25 | MAR '26 | JUN '26 | SEP '26 | |
|---|---|---|---|---|---|
| Revenue | 412 | 476 | 514 | 534 | 576 |
| Operating profit | 94 | 108 | 119 | 129 | 144 |
| Operating margin | 22.9% | 22.7% | 23.1% | 24.2% | 25.0% |
| Other income | 1 | 4 | 3 | 6 | 2 |
| Interest | 11 | 10 | 10 | 9 | 11 |
| Depreciation | 12 | 12 | 12 | 15 | 18 |
| Profit before tax | 72 | 91 | 99 | 110 | 117 |
| Tax | 18 | 18 | 22 | 26 | 26 |
| Net profit | 54 | 73 | 77 | 85 | 90 |
| EPS ₹ | 3.49 | 4.46 | 4.66 | 5.13 | 5.47 |
| Revenue YoY | — | — | — | — | 39.9% |
| Profit YoY | — | — | — | — | 68.0% |
Returns & margins
trailing-twelve-month, per quarter| JUN '26 | SEP '26 | |
|---|---|---|
| ROE | 22.4% | 22.9% |
| ROCE | 26.6% | 25.2% |
| Net margin | 14.9% | 15.5% |
| EBITDA margin | 23.3% | 23.8% |
| Debt / equity | 0.20 | 0.28 |
| Interest coverage | 10.09 | 11.20 |
| Asset turnover | 0.83 | 0.76 |
Balance sheet
equity vs borrowings over time · ₹ crore| SEP '25 | MAR '26 | SEP '26 | |
|---|---|---|---|
| Share capital | 15 | 17 | 17 |
| Other equity / reserves | 632 | 1,272 | 1,400 |
| Total equity | 647 | 1,289 | 1,416 |
| Borrowings | 517 | 259 | 398 |
| Current liabilities | 893 | 836 | 953 |
| Non-current liabilities | 242 | 202 | 377 |
| Total assets | 1,782 | 2,327 | 2,761 |
| Property, plant & equipment | 443 | 467 | 526 |
| Capital work-in-progress | 34 | 40 | 90 |
| Investments | 0 | 27 | 29 |
| Inventories | 630 | 729 | 790 |
| Receivables | 345 | 509 | 578 |
| Cash & equivalents | 137 | 186 | 209 |
Cash flow
annual · ₹ crore · line = free cash flow| FY26 | |
|---|---|
| Cash from operations | 205 |
| Cash from investing | -410 |
| Cash from financing | 283 |
| Capex | 229 |
| Free cash flow | -24 |
| Dividends paid | 0 |
Where the assets sit
Sep '26 · ₹ crorePeer comparison
largest in Healthcare · this company in bold| Company | Market cap ₹cr | Price | P/E | P/B | ROE |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,270 | 1,860.00 | 40.7 | 5.00 | 12.3% |
| Divi's Laboratories Ltd. | 2,73,493 | 10,320.50 | 93.5 | 16.32 | 17.5% |
| Torrent Pharmaceuticals Ltd. | 1,80,671 | 4,750.00 | 85.1 | 9.83 | 11.6% |
| Laurus Labs Ltd. | 1,26,430 | 2,340.00 | 94.4 | 20.86 | 22.1% |
| Apollo Hospitals Enterprise Ltd. | 1,21,453 | 8,446.00 | 54.2 | 11.45 | 21.1% |
| Zydus Lifesciences Ltd. | 1,19,550 | 1,197.90 | 28.6 | 4.30 | 15.0% |
| Dr. Reddy's Laboratories Ltd. | 1,14,646 | 1,373.00 | 40.9 | 2.95 | 7.2% |
| Cipla Ltd. | 1,13,988 | 1,411.00 | 39.3 | 3.22 | 8.2% |
| Mankind Pharma Ltd. | 1,04,902 | 2,540.00 | 46.7 | 5.97 | 12.8% |
| Aurobindo Pharma Ltd. | 1,03,572 | 1,800.00 | 26.0 | 2.63 | 10.1% |
| Rubicon Research Ltd. | 27,466 | 1,659.30 | 84.6 | 19.39 | 22.9% |
StoxGud checklist: Bullish setup · 8/10
- Price above 50-day average
- Price above 200-day average
- 50-day average above 200-day (uptrend)
- RSI in healthy 40–70 zone
- Positive 1-year return
- Return on equity above 15%
- Debt to equity below 1
- Revenue growing year on year
- Net profit margin above 10%
- P/E below industry median
A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.
Returns & technicals
Compare Rubicon Research Ltd. with
FAQs
What is the share price of Rubicon Research Ltd.?
Rubicon Research Ltd. (RUBICON) closed at ₹1,659.30 on NSE on 06 Nov 2026.
What is the market cap of Rubicon Research Ltd.?
₹27,466 crore at the latest close.
What is the P/E ratio of Rubicon Research Ltd.?
84.6, on trailing-twelve-month earnings from its filings.
How fast is Rubicon Research Ltd. growing?
Rubicon Research Ltd.: Latest-quarter revenue is up 39.9% year on year, profit up 68.0%.
How profitable is Rubicon Research Ltd.?
On a trailing-twelve-month basis return on equity is 22.9%, return on capital employed 25.2%, operating margin 23.8%, net margin 15.5%.
How much debt does Rubicon Research Ltd. have?
Rubicon Research Ltd. is lightly geared: debt to equity is 0.28 with borrowings of ₹398 cr against cash of ₹209 cr (balance sheet of 2026-09-30). Operating profit covers interest 11.2 times.
Financials parsed from Rubicon Research Ltd.'s own XBRL filings to NSE (consolidated), ₹ crore unless marked. Quarterly from SEP '25, annual from FY26, balance sheet from Sep '25. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.